OPTIMIZATION OF PROTEOLYTIC CLEAVAGE OF PEPTIDE AFFINITY

Information

  • Research Project
  • 2192656
  • ApplicationId
    2192656
  • Core Project Number
    R43GM053307
  • Full Project Number
    1R43GM053307-01
  • Serial Number
    53307
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1995 - 29 years ago
  • Project End Date
    3/31/1996 - 28 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1995 - 29 years ago
  • Budget End Date
    3/31/1996 - 28 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/21/1995 - 29 years ago
Organizations

OPTIMIZATION OF PROTEOLYTIC CLEAVAGE OF PEPTIDE AFFINITY

The goal of this proposal is to develop a peptide cleavage system which will improve the efficiency and specificity of cleaving affinity tag peptides from recombinant proteins. The purpose is to simplify the purification of recombinant proteins from either prokaryotic or eukaryotic expression systems and ensure no additional terminal amino acids will remain on the final product. Although fusion tag peptides and peptidases are commercially available, the efficiency and specificity of cleavage is not optimal and often results in low yields of the desired protein product. Development of an optimized cleavage system will impact research labs as well as therapeutics and production processes by increasing the efficiency of studying new proteins and reducing the cost of protein production. A selectable M13 filamentous phage display system will be used to identify optimal combinations of cleavage sites and peptidases. Two approaches will be pursued: one targeting the peptide cleavage site, and the other targeting the enzymatic domain of the peptidase. PROPOSED COMMERCIAL APPLICATION: Several commercial applications will result from this work. The vectors constructed to perform the screening experiment will be marketable cloning vectors. The sequences identified through the research will be inserted into optimized protein expression vector. Modified peptidases will be marketed if they prove to be superior to naturally found enzymes.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    STRATAGENE
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92037
  • Organization District
    UNITED STATES